Gabrielle Tova Prince, M.D.

Headshot of Gabrielle Tova Prince

Languages: English, Hebrew, Spanish


Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders more

Research Interests

New Therapies for Patients with Acute and Chronic Leukemias; Myelodysplastic Syndrome more

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment


Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231 map

The Bunting Blaustein Cancer Research Building

1650 Orleans Street
Baltimore, MD 21287 map


Dr. Gabrielle Prince is an Oncologist in Baltimore caring for patients with leukemias and other blood and bone marrow disorders.  She is viewed regionally as a clinical expert in the care of patients with these disorders and has served as the Principal Investigator for numerous clinical trials studying new treatments for the most challenging clinical cases. 

Dr. Prince received her undergraduate degree in Biomedical Engineering from Columbia University (New York, NY), earned her M.D. at the State University of New York (Brooklyn, NY), completed her Residency at Columbia University Medical Center-New York Presbyterian (New York, NY), and Fellowship in Medical Oncology at Johns Hopkins (Baltimore, MD). Dr. Prince joined the Johns Hopkins faculty in 2014 at the completion of her training.

Her main research interests include drug development for patients with AML, MDS, and MPDs.  She has been involved in several clinical trials that helped lead to FDA approval of those new drugs and she remains interested in helping the program maintain a broad-based clinical trials portfolio. more

Departments / Divisions

  • Medicine at Sibley Memorial Hospital
  • Oncology

Centers & Institutes



  • MD; SUNY Downstate Medical Center College of Medicine (2007)


  • Internal Medicine; New York-Presbyterian/Weill Cornell Medical Center (2010)


  • Hematology and Medical Oncology; Johns Hopkins University School of Medicine (2013)

Research & Publications

Research Summary

Dr. Prince’s research focuses on moving new and promising drugs into the clinic for patients with challenging to treat acute leukemias, MDS, and MPDs.

Clinical Trial Keywords

AMl, MDS, Acute and Chronic Leukemias, Myeloid Disorders and Bone Marrow Malignancies

Selected Publications

View all on PubMed

Goswami M, Prince G, Biancotto A, Moir S, Kardava L, Santich BH, Cheung F, Kotliarov Y, Chen J, Shi R, Zhou H, Golding H, Manischewitz J, King L, Kunz LM, Noonan K, Borrello IM, Smith BD, Hourigan CS.Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy. J Transl Med. 2017 Jul 10;15(1):155. doi: 10.1186/s12967-017-1252-2.PMID: 28693586

DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM.Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2.PMID: 29860938

Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020 Feb 13;135(7):463-471. doi: 10.1182/blood.2019002140.PMID: 31841594

Robinson TM, Prince GT, Thoburn C, Warlick E, Ferguson A, Kasamon YL, Borrello IM, Hess A, Smith BD.Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients. Leuk Lymphoma. 2018 Dec;59(12):2801-2811. doi: 10.1080/10428194.2018.1443449. Epub 2018 Apr 4.PMID: 29616857

Zeidner JF, Knaus HA, Zeidan AM, Blackford AL, Montiel-Esparza R, Hackl H, Prince GT, Gondek LP, Ghiaur G, Showel MM, DeZern AE, Pratz KW, Douglas Smith B, Levis MJ, Gore S, Coombs CC, Foster MC, Streicher H, Karp JE, Luznik L, Gojo I.Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS. Leukemia. 2020 Jun;34(6):1563-1576. doi: 10.1038/s41375-019-0693-4. Epub 2020 Jan 3.PMID: 31900407

Activities & Honors


  • American Society of Hematology, 1996

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

Is this you? Edit Profile
back to top button